Russell Michael, Wilkinson Michelle, Hayes Andrew
Sarcoma and Melanoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Institute of Cancer Research, 237 Fulham Road, London, SW3 6JJ UK.
Indian J Surg Oncol. 2024 Sep;15(3):499-508. doi: 10.1007/s13193-024-01920-2. Epub 2024 Apr 8.
Isolated limb perfusion (ILP) is a regional chemotherapy technique used in the treatment of locally advanced or unresectable extremity soft tissue sarcoma (ESTS) or malignant melanoma (MM) of the limbs. It allows for high concentrations of chemotherapeutic agents to be perfused in the limb while minimising the risk of systemic side-effects. While the technique has been utilized for decades, the role of ILP has evolved as other treatment strategies have become available. Current indications for ILP in sarcoma include induction in unresectable ESTS to allow for future definitive limb preservation procedures as well as definitive treatment of unresectable, multifocal ESTS. In MM, ILP is typically used in unresectable in-transit melanoma, and rarely as an alternative to amputation in bulky, symptomatic extremity disease. This review seeks to summarise the current evidence base and indications for ILP as well as present some technical insights from a high-volume United Kingdom (UK) unit.
孤立肢体灌注(ILP)是一种区域化疗技术,用于治疗局部晚期或无法切除的肢体软组织肉瘤(ESTS)或肢体恶性黑色素瘤(MM)。它能使高浓度化疗药物灌注到肢体中,同时将全身副作用的风险降至最低。尽管该技术已应用数十年,但随着其他治疗策略的出现,ILP的作用也在不断演变。目前ILP在肉瘤治疗中的适应证包括:对无法切除的ESTS进行诱导治疗,以便未来进行确定性的肢体保留手术;以及对无法切除的多灶性ESTS进行确定性治疗。在MM中,ILP通常用于无法切除的移行性黑色素瘤,在体积较大、有症状的肢体疾病中,很少作为截肢的替代方法。本综述旨在总结当前关于ILP的证据基础和适应证,并介绍来自英国一个大型治疗单位的一些技术见解。